Drug trial aims to save brains after heart stops
NCT ID NCT00999583
Summary
This large Phase 3 trial tested whether giving a high dose of a drug called erythropoietin (epoetin alpha) soon after a cardiac arrest could help protect the brain and improve recovery. The study involved 500 comatose survivors who received either the standard treatment alone or the standard treatment plus the experimental drug. The main goal was to see if more patients receiving the drug regained good brain function with little disability 60 days later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMATOSE SURVIVORS OF CARDIAC ARREST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical intensive care unit of Cochin-St Vincent de Paul university Hospital
Paris, 75679, France
Conditions
Explore the condition pages connected to this study.